Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021
New data on Abivax's phase 2b maintenance results, including the first 101 patients who completed 48 weeks of daily treatment with ABX464, will be made public for the first time during the oral presentation.
Abstract: #AS-UEG-2021-02909 Session: Late-breaking Abstracts III: Clinical trials in IBD Talk: Oral ABX464 QD is efficacious and safe during phase 2b induction and maintenance treatment of ulcerative colitis Time: October 4, 2021 - at 10:42-10:54 am CEST (4:42-5:54 am EST) Presenter: Prof. S?verine Vermeire, M.D., Ph.D., Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator of the ABX464 phase 2a and phase 2b clinical studies in UC
Abivax Live Industry Symposium
The symposium will be chaired by Prof. Bruce Sands, M.D., M.S., of the Icahn School of Medicine at Mount Sinai, New York City, NY, USA. The focus of the symposium will be on the continued need for novel drugs in IBD, the clinical data from the phase 2b induction and maintenance studies with ABX464 in UC and the novel mechanism of action of ABX464.
Following the presentations, participants will have the opportunity to ask questions during the live Q&A session.
Title: ABX464, a novel anti-inflammatory drug-candidate for the treatment of ulcerative colitis Time: October 4, 2021 - 1:00-2:00 pm CEST (7:00-8:00 am EST) Program: The continued need to develop novel drugs for ulcerative colitisProf. William Sandborn, M.D. University of California San Diego School of Medicine and Co-Founder and Chief Medical Officer at Shoreline Biosciences, CA, USA ? ABX464 novel mechanism of action: Upregulation of the anti-inflammatory microRNA miR-124 Didier Scherrer, Ph.D. Vice-President R&D, Abivax, France ? Safety and efficacy of ABX464 in a phase 2b study in ulcerative colitis Prof. Bruce Sands, M.D., M.S. Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York City, NY, USA ? Live Q&A session
Registered UEG Week participants can follow the live symposium and view the subsequently provided on-demand replay under the following link: https://virtualweek.ueg.eu/symposium/is-10
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mn?mo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Abivax Communications Regina Jehleregina.email@example.com +33 6 24 50 69 63 InvestorsLifeSci Advisors Ligia Vela-Reidlvelafirstname.lastname@example.org +44 7413 825310 Press Relations & Investors EuropeMC Services AG Anne Henneckeanne.email@example.com +49 211 529 252 22 Public Relations FranceActifin Ghislaine Gasparettoggasparetto@actifin.fr +33 6 21 10 49 24 Public Relations FranceDGM Conseil Thomas Roborel de Climensthomasdeclimens@dgm-conseil.fr +33 6 14 50 15 84 Public Relations USA Rooney Partners LLC Jeanene Timberlakejtimberlake@rooneypartners.com +1 646 770 8858
28.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de